Street View: CVS split could be the right call, but raises questions
BUZZ-Street View: CVS split could be the right call, but raises questions ** CVS Health CVS.N said on Wednesday it will split in two, separating its retail pharmacies from the Aetna insurance business and pharmacy-benefit operations in a major unwinding of the $117 billion healthcare conglomerate it spent years building
CONCERNS REMAIN
** BofA Global Research ("buy," PO: $100) says that "excluding the announced separation, we believe the update broadly de-risks the setup heading into 2027"
** Jefferies ("buy," PT: $103) says the decision to separate businesses ahead of an "upcoming wave of local laws" challenging CVS's strategy is the right move that could reduce overhang on the stock
** Barclays ("overweight," PT: $108) says a primary investor concern is on the lack of financial detail around the break up, which is at odds with the minimum $500 mln cost synergy outlined when CVS acquired Caremark 20 years ago
** RBC Capital Markets ("outperform," PT: $113) says the announcement represents a "surprising strategic departure" from last year's investor day; says several important questions remain
(Reporting by Kanchana Chakravarty in Bengaluru)
Recent news on CVS Health
See all newsHealth Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
US health insurers fall for third day on CMS audit proposal, Medicare-for-All concerns
Health insurers extend decline on proposed new rule to curb fraud
Health insurers extend decline on proposed new rule to curb fraud
UnitedHealthcare to expand program paying pharmacists for medical services